注射性包封的多能干细胞聚集物的生物工程用于心肌梗死的治疗。

Department of Biomedical Engineering, The Ohio State University, Columbus, Ohio 43210, USA.

Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio 43210, USA.

Nat Commun. 2016 Oct 27;7:13306. doi: 10.1038/ncomms13306.

It is difficult to achieve minimally invasive injectable cell delivery while maintaining high cell retention and animal survival for in vivo stem cell therapy of myocardial infarction. Here we show that pluripotent stem cell aggregates pre-differentiated into the early cardiac lineage and encapsulated in a biocompatible and biodegradable micromatrix, are suitable for injectable delivery. This method significantly improves the survival of the injected cells by more than six-fold compared with the conventional practice of injecting single cells, and effectively prevents teratoma formation. Moreover, this method significantly enhances cardiac function and survival of animals after myocardial infarction, as a result of a localized immunosuppression effect of the micromatrix and the in situ cardiac regeneration by the injected cells.

在进行心肌梗死的体内干细胞治疗时，很难在保持高细胞保留率和动物存活率的情况下实现微创可注射细胞递送。在这里，我们展示了预先定向分化为早期心脏谱系的多能干细胞聚集物，并封装在生物相容性和可生物降解的微基质中，适合可注射递送。与传统的注射单细胞相比，这种方法使注射细胞的存活率提高了六倍以上，并且有效地防止了畸胎瘤的形成。此外，由于微基质的局部免疫抑制作用和注射细胞的原位心脏再生，该方法显著增强了心肌梗死后动物的心脏功能和存活率。